The Role of Risk Stratification in Myeloma Treatment

Dr. Sagar Lonyal has been doing myeloma for a couple of decades. His approach is to deepen the response early, consolidate everybody with a transplant and then go right now with single agent lentilimide maintenance. The availability of anti-CD38 antibodies has thrown a lot of this into confusion,. I think the presence of carfilzumib as an alternative proteosome inhibitor has also further confused the field.